VSVeronica Skarpeteig

Veronica Skarpeteig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Veronica Skarpeteig has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Anine Larsen Ottestad

    Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

    1 shared publication
  • Elisabeth Fritzke Emdal

    Department of Pathology, Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, 7030 Trondheim, Norway

    1 shared publication
  • Hong Yan Dai

    Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU—Norwegian University of Science and Technology, 7034 Trondheim, Norway

    1 shared publication
  • Mo Huang

    Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 7030 Trondheim, Norway

    1 shared publication
  • Robin Mjelle

    Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

    1 shared publication

Latest Publications

  • Open Access

    Assessment of Two Commercial Comprehensive Gene Panels for Personalized Cancer Treatment

    by Anine Larsen Ottestad, Mo Huang, Elisabeth Fritzke Emdal, Robin Mjelle, Veronica Skarpeteig, Hong Yan Dai

    (1) Background: Analysis of tumor DNA by next-generation sequencing (NGS) plays various roles in the classification and management of cancer. This study aimed to assess the performance of two similar and large, comprehensive gene panels with a focus on clinically relevant variant detection and tumor mutation burden (TMB) assessment; (2) Methods: DNA from 19 diagnostic small cell lung cancer biopsies and an AcroMetrix™ assessment sample with >500 mutations were sequenced using Oncomine™ Comprehensive Assay Plus (OCAP) on the Ion Torrent platform and TruSight Oncology 500 Assay (TSO500) on the Illumina platform; (3) Results: OCAP and TSO500 achieved comparable NGS quality, such as mean read coverage and mean coverage uniformity. A total of 100% of the variants in the diagnostic samples and 80% of the variants in the AcroMetrix™ assessment sample were detected by both panels, and the panels reported highly similar variant allele frequency. A proportion of 14/19 (74%) samples were classified in the same TMB category; (4) Conclusions: Comparable results were obtained using OCAP and TSO500, suggesting that both panels could be applied to screen patients for enrolment in personalized cancer treatment trials.